The global viral conjunctivitis pipeline drugs market size is projected to register a high CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing healthcare expenditure and accessibility of diagnostic test.
Viral conjunctivitis is a type of eyes infection usually caused by adenovirus. Some of the other viruses that causes conjunctival infection include varicella-zoster virus, herpes simplex virus, poxvirus, and picornavirus. The common symptoms of viral conjunctivitis include tearing, light sensitivity, redness, and itchy eyes. Patients suffering from viral conjunctivitis are generally recommended to avoid sharing towels, touching their eyes, pillow cases, and napkins with other family members. In addition, the virus transmission can be occurred through coincidental inoculation of particles from swimming pools, hands, and by contact from droplets of infected tracks.
The U.S. Food and Drug Administration (FDA) has not sanctioned even one drug as of now for the treatment of the infection. Hence, rapid promotion of novel drugs is attributed to impact the market positively during the forecast period. In the U.S., every year around millions of people are affected by acute conjunctivitis. Currently, APD-209 and FST-100 are the key pipeline drugs for the treatment though they are still in early phase medical trials and are expected to be launched in the coming years.
Market Trends, Drivers, Restraints, and Opportunities
- Accessibility of diagnostic test and increasing healthcare expenditure globally are expected to propel the market growth.
- Rising awareness among people and increased R&D activities by healthcare authorities are expected to boost the market growth.
- Increasing the demand for viral conjunctivitis array of drugs is expected to be a major factor to accelerate the market growth.
- High prevalence rate of viral conjunctivitis in some regions such as Japan and Brazil, but there are no efficacious permitted drugs in the market. This is expected to boost the growth of the global market.
- High cost, appropriate diagnosis, and less awareness regarding advanced technologies are key challenges that can hamper the market growth.
Scope of the Report
The report on the global viral conjunctivitis pipeline drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Viral Conjunctivitis Pipeline Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Pipeline Drugs (Early Stage Preclinical Trials, FST-100, and APD-209)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Allergan plc; Shire plc; NanoViricides, Inc.; Novartis International AG; NovaBay Pharmaceuticals, Inc.; Panoptes Pharma GES.M.B.H.; NicOx S.A.; and Adenovir Pharma AB
Market Segment Insights
Early stage preclinical trials segment is expected to grow at a rapid pace
Based on pipeline drugs, the global viral conjunctivitis pipeline drugs market is segregated into early stage preclinical trials, FST-100, and APD-209. The early stage preclinical trials segment is anticipated to grow at a rapid pace in the coming years owing to advancement in technology and growing awareness in people. However, the APD-209 segment is expected to account for a key share of the market during the forecast period due to development procedures of APD-209 and ongoing clinical trials. Moreover, introduction of advanced diagnostic technique is expected to further propel the segment growth.
Region is anticipated to constitute a key market share
In terms of regions, the market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America accounted for a key share of the market in 2019 and is anticipated to constitute a key market share during the forecast period owing to rising awareness regarding inappropriate utilization of antibiotics and ongoing clinical trials. The market of Asia Pacific, however, is anticipated to expand at a robust growth pace during the forecast period due to accessibility & amplified application of diagnostic tests in the region.
Segments Covered in the Report
The global viral conjunctivitis pipeline drugs market has been segmented on the basis of
- Early Stage Preclinical Trials
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- Allergan plc
- Shire plc
- NanoViricides, Inc.
- Novartis International AG
- NovaBay Pharmaceuticals, Inc.
- Panoptes Pharma GES.M.B.H.
- NicOx S.A.
- Adenovir Pharma AB
Key players competing in the global viral conjunctivitis pipeline drugs market are Allergan plc; Shire plc; NanoViricides, Inc.; Novartis International AG; NovaBay Pharmaceuticals, Inc.; Panoptes Pharma GES.M.B.H.; NicOx S.A.; and Adenovir Pharma AB. Some of these main market players are continuously engaged in various market development activities such as mergers and acquisitions, research and developments, investments for innovative products, and collaborations to secure a competitive edge in the market.